Core Insights - Processa Pharmaceuticals, Inc. is participating in the 2025 BIO International Convention to showcase its Next Generation Cancer (NGC) therapies [1][4] - The company will provide updates on its strategic direction and clinical progress, particularly focusing on its lead asset NGC-Cap, which is in a Phase 2 trial for metastatic breast cancer [2][3] - The CEO emphasized the opportunity to engage with potential partners committed to developing safer and more effective cancer treatments [3] Company Overview - Processa Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing NGC drugs that enhance safety and efficacy [5] - The NGC drugs are modifications of existing FDA-approved oncology therapies, aiming to alter metabolism and distribution while maintaining cancer cell-killing mechanisms [5] - The company's strategy combines a novel oncology pipeline with proven active molecules and a Regulatory Science Approach to improve therapy options for cancer patients [5]